Vicente Felipo / Mild cognitive and motor impairment: assessment, mechanisms and treatments
Upcoming SlideShare
Loading in...5
×
 

Vicente Felipo / Mild cognitive and motor impairment: assessment, mechanisms and treatments

on

  • 165 views

Presentation given by Vicente Felipo from Príncipe Felipe Research Center in the framework of the Emergence Forum Barcelona ...

Presentation given by Vicente Felipo from Príncipe Felipe Research Center in the framework of the Emergence Forum Barcelona

Biocat organized the Barcelona Emergence Forum (April 10-11th, 2014, Congress Palace, Montjuïc) supported by the TRANSBIO SUDOE, a translational cooperation project dedicated to innovation in life sciences in South-West Europe. The Barcelona Emergence Forum contributed to bringing together Academics, Companies, Investment Entities, Technology Platforms and Technology Transfer Offices from Spain, France and Portugal to set up collaborative projects on Human Health & Agro-food Innovation.
More information at: http://www.b2match.eu/emergenceforum2014

Statistics

Views

Total Views
165
Views on SlideShare
164
Embed Views
1

Actions

Likes
1
Downloads
1
Comments
0

1 Embed 1

http://www.b2match.eu 1

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Vicente Felipo / Mild cognitive and motor impairment: assessment, mechanisms and treatments Vicente Felipo / Mild cognitive and motor impairment: assessment, mechanisms and treatments Presentation Transcript

    • MILD COGNITIVE AND MOTOR IMPAIRMENT: ASSESSMENT, MECHANISMS AND TREATMENT Vicente Felipo Laboratory of Neurobiology, NEUROCIPF Centro de Investigación Príncipe Felipe Valencia, Spain vfelipo@cipf.es http://www.neurocipf.es/
    • AIMS: In animal models: 1. Unveil the molecular mechanisms leading to cognitive / motor impairment 2. Identify new therapeutic targets for its treatment 3. Design and assess new therapeutic procedures to reverse cognitive / motor impairment
    • AIMS: 4. To study in patients the mechanisms, diagnosis and treatment of neurological impairment 5. Bring to the clinic the therapeutic procedures developed in animal models 6. Identify early diagnostic procedures for neurological impairment 7. Bring to the clinic the diagnostic procedures identified
    • In patients Identifying biomarkers in blood and develop tools for early diagnosis of cognitive impairment at preclinical stage. Perform psychometric tests assessing different cognitive and motor functions: attention, visuo-motor coordination, bimanual coordiantion, mental porcessing speed, etc
    • We have identified the first peripheral biomarker (3-nitro- tyrosine in serum) to diagnose minimal hepatic encephalopathy in patients with liver cirrhosis. The procedure has been patented We wish to develop a diagnostic tool
    • We perform the following types of studies: 1 Analysis of cognitive and motor functions in rats 2 Study of the alterations of cognitive and motor functions in pathological situations and of the mechanisms responsible for the alterations. 3 Evaluation of therapeutic treatments to restore the cognitive and/or motor functions. 4 Analysis of the possible secondary effects of drugs on cognitive and motor function.
    • 5 Analysis of circadian rhythms of activity and of their alterations in pathological situations or by the use of drugs 6 Analysis of the electroencephalogram (EEG) and of their alterations in pathological situations or by the use of drugs 7 . Analysis of a wide variety of compounds in blood, brain or other tissues by different techniques (HPLC, immunohistochemistry, western blott, ELISA, etc): inflammatory markers, neurotransmitters, amino acids, neurosteroids, nitrotyrosine, markers of oxidative stress, any protein by immunoblotting, nitration of proteins, etc.
    • 0 2 4 6 8 10 12 14 16 18 20 22 24 26 0 200 400 600 800 1000 1200 CONTROL HA *** *** *** ** ** * ZT Ambulatorycounts MOTOR COORDINATION Beam walking Rotarod MOTOR ACTIVITY Circadian rhythms AnxietyWheels
    • Y maze, conditional discrimination Spatial learning and memory, Morris water maze Spatial learning and memory, Radial maze Object recognition Object location Active / passive avoidance COGNITIVE FUNCTION
    • NEUROLOGICAL ALTERATIONS Motor activity Motor coordination Learning Y maze MOLECULAR MECHANISMS INVOLVED Dopamine-glutamate neurotransmission in NAcc GABA neurotransmission in cerebellum Function of the glutamate- NO-cGMP pathway in cerebellum
    • Y maze conditional discrimination test Modulated by the Glu-NO-cGMP pathway Experim Control The walls may be white or black. When they are white, food is put on the right; when they are black, on the left. Rats must learn where is the food depending on the color of the wall Ca 2 + Glu CM N O . GC cGMP Ca 2+ cGMP NOS
    • COOPERATION OFFERED includes, but not restricted to: 1) Participate as partners in European or other projects. We have long expertise and have provided this type of studies in 8 different European projects. 2) Provide this type of studies to pharmaceutical or other type of companies as a service to test beneficial effects of new drugs (or secondary effects). We have also experience in this type of collaboration. 3) Collaboration in research projects of interest vfelipo@cipf.es http://www.neurocipf.es
    • LABORATORY OF NEUROBIOLOGY Vicente Felipo vfelipo@cipf.es Programa Prometeo GV SAF